Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Cancer
Auteurs principaux: Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, Morris, Michael J.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6299293/
https://ncbi.nlm.nih.gov/pubmed/30270112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2018.09.022
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires